TRAIL in cancer therapy: present and future challenges.

Abstract : Since its identification in 1995, TNF-related apoptosis-inducing ligand (TRAIL) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. In contrast to other members of the TNF superfamily, TRAIL administration in vivo is safe. The relative absence of toxic side effects of this naturally occurring cytokine, in addition to its antitumoural properties, has led to its preclinical evaluation. However, despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity or efficiency. An appropriate understanding of its physiological relevance, and of the mechanisms controlling cancer cells escape from TRAIL-induced cell death, will be required to optimally use the cytokine in clinics. The present review focuses on recent advances in the understanding of TRAIL signal transduction and discusses the existing and future challenges of TRAIL-based cancer therapy development.
Type de document :
Article dans une revue
Expert Opin Ther Targets, 2007, 11 (10), pp.1299-314. 〈10.1517/14728222.11.10.1299〉
Liste complète des métadonnées

Littérature citée [62 références]  Voir  Masquer  Télécharger
Contributeur : Olivier Micheau <>
Soumis le : lundi 18 octobre 2010 - 10:49:32
Dernière modification le : vendredi 8 juin 2018 - 14:50:12
Document(s) archivé(s) le : mercredi 19 janvier 2011 - 02:40:18


Fichiers produits par l'(les) auteur(s)




Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, Eric Solary, Olivier Micheau. TRAIL in cancer therapy: present and future challenges.. Expert Opin Ther Targets, 2007, 11 (10), pp.1299-314. 〈10.1517/14728222.11.10.1299〉. 〈inserm-00527108〉



Consultations de la notice


Téléchargements de fichiers